Artal Group S.A. Gossamer Bio, Inc. Transaction History

Artal Group S.A.

$1.86 Billion
Q1 2024

A detailed history of Artal Group S.A. transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Artal Group S.A. holds 207,000 shares of GOSS stock, worth $186,300. This represents 0.01% of its overall portfolio holdings.

Number of Shares

207,000

Previous 207,000 -0.0%

Holding current value

$186,300

Previous $244,000 -0.0%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.8 - $1.51 $1 Million - $1.89 Million	1,250,000 Added 10.37%	13,308,968 $15.7 Million
Q4 2023 Feb 09, 2024	BUY	$0.48 - $1.08 $2.72 Million - $6.11 Million	5,659,149 Added 88.43%	12,058,968 $11 Million
Q3 2023 Nov 13, 2023	BUY	$0.78 - $1.82 $2.63 Million - $6.14 Million	3,371,648 Added 111.34%	6,399,819 $5.33 Million
Q1 2023 May 12, 2023	SELL	$0.96 - $2.92 $209,714 - $637,882	-218,453 Reduced 6.73%	3,028,171 $3.82 Million
Q3 2022 Nov 14, 2022	BUY	$7.21 - $14.88 $6.4 Million - $13.2 Million	887,656 Added 37.63%	3,246,624 $38.9 Million

Q3 2020 Nov 13, 2020	SELL	$11.3 - $14.75 $3.39 Million - $4.43 Million	-300,000 Reduced 11.28%	2,358,968 $29.3 Million
Q2 2020 Aug 14, 2020	BUY	$9.52 - $15.98 $8.09 Million - $13.6 Million	850,000 Added 46.99%	2,658,968 $34.6 Million
Q1 2020 May 14, 2020	BUY	$8.0 - $15.48 $1.6 Million - $3.1 Million	200,000 Added 12.43%	1,808,968 $18.4 Million
Q2 2019 Aug 09, 2019	SELL	$16.12 - $22.89 $806,000 - $1.14 Million	-50,000 Reduced 3.01%	1,608,968 $35.7 Million
Q1 2019 May 10, 2019	BUY	$17.58 - $23.97 $29.2 Million - $39.8 Million	1,658,968 New	1,658,968 $36 Million

Others Institutions Holding GOSS

# of Institutions

114

Shares Held

190M

Call Options Held

405K

Put Options Held

490K

View Full List

About Gossamer Bio, Inc.

Ticker GOSS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,954,000
Market Cap $84.6M
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...

More about GOSS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

News

Stay updated on Artal Group S.A. with notifications on news.

Account